Fig. 1.

Expression of FoxP3 in CD4⁺CD25⁺CD127⁻ Tregs in patients receiving the PSA-TRICOM vaccine. a Expression of FoxP3 in CD4⁺CD25⁺CD127⁻ Tregs. PBMCs from a patient were analyzed by flow cytometry after cell surface staining with FITC-conjugated anti-CD4, phycoerythrin-conjugated anti-CD127, PECy7-conjugated anti-CD25, and intracellular staining with APC-conjugated anti-FoxP3. b Percentage of CD4⁺CD25⁺CD127⁻Foxp3⁺ Tregs in CD4 population pre- and post-vaccination in the peripheral blood of all patients enrolled on study. c Percentage of CD4⁺CD25⁺CD127⁻Foxp3⁺ Tregs in CD4 population pre- and post-vaccination in the peripheral blood of patients with OS > HPS. d Percentage of CD4⁺CD25⁺CD127⁻Foxp3⁺ Tregs in CD4 population pre- and post-vaccination in the peripheral blood of patients with OS < HPS. There were no significant differences in levels of Tregs pre- and post-vaccination among patients on study, patients with OS > HPS, and patients with OS < HPS (P = 0.1, P = 0.107, and P = 0.745, respectively)